stockportfolio.pro
The Oncology Institute, Inc. (TOI)
Healthcare · Medical Care Facilities · NasdaqCM
The Oncology Institute, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $187.51M | $203.00M | $252.48M | $324.24M | $393.41M | $502.73M |
| Gross profit | — | — | $52.09M | $59.57M | $54.00M | $76.44M |
| Net income | $-14.32M | $-10.93M | $152,000 | $-83.07M | $-64.66M | $-60.61M |
| Net margin | -7.6% | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
Source: The Oncology Institute, Inc. SEC filings (10-K).
Explore 6 years of The Oncology Institute, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TOI in your portfolio →
The Oncology Institute, Inc. financial history by metric
About The Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
The Oncology Institute, Inc. — frequently asked questions
What is The Oncology Institute, Inc.'s revenue?
The Oncology Institute, Inc. (TOI) reported revenue of $502.73M for fiscal year 2025, up 27.8% from the prior year, according to its SEC filings.
Is The Oncology Institute, Inc. profitable?
No — TOI reported a net loss of $-60.61M in fiscal 2025.
What is TOI's P/E ratio?
The Oncology Institute, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is The Oncology Institute, Inc. growing?
TOI's revenue grew at roughly 21.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does The Oncology Institute, Inc. have?
As of fiscal year 2025, TOI carried roughly $77.40M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is The Oncology Institute, Inc.'s gross margin?
TOI's gross margin was 15.2% in fiscal 2025 — gross profit of $76.44M on revenue of $502.73M.
What is The Oncology Institute, Inc.'s market cap?
The Oncology Institute, Inc. (TOI) has a market capitalization of about $486.42M, based on the latest data in our nightly-refreshed cache.
When does The Oncology Institute, Inc.'s fiscal year end?
TOI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from The Oncology Institute, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.